会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Breast cancer resistance protein (BCRP) inhibitor
    • 乳腺癌抗性蛋白(BCRP)抑制剂
    • US07371773B2
    • 2008-05-13
    • US10544064
    • 2004-02-03
    • Ryuta YamazakiYukiko NishiyamaTomio FurutaTakeshi MatsuzakiHiroshi HatanoOh YoshidaMasato NagaokaRitsuo AiyamaShusuke HashimotoYoshikazu Sugimoto
    • Ryuta YamazakiYukiko NishiyamaTomio FurutaTakeshi MatsuzakiHiroshi HatanoOh YoshidaMasato NagaokaRitsuo AiyamaShusuke HashimotoYoshikazu Sugimoto
    • A61K31/415
    • C07D211/58A61K31/277A61K31/7034C07C255/37C07D317/60
    • The invention provides a drug which inhibits BCRP.A breast cancer resistance protein inhibitor containing, as an active ingredient, a diphenylacrylonitrile derivative represented by the following formula (1): [wherein, each of 8 R's, which are the same or different from one another, represents a hydrogen atom, a hydroxyl group, a nitro group, an amino group, an acetylamino group (—NHCOCH3 group); a cyano group (—CN group); a formyl group (—CHO group), —COOR1 (R1 is hydrogen or C1-C4 alkyl), —O(CH2)nCOOR2 (n=1−7: R2 is hydrogen or C1-C4 alkyl), —OOCCH2CH2COOR3 (R3 is hydrogen, C1-C4 alkyl, (Z)-2-(3,4-dimethoxy-phenyl)-3-(4-hydroxy-phenyl)-acrylonitrile, or glycopyranosyl), a C1-C8 alkoxy group, a C1-C4 alkyl group, a halogen atom, a C1-C4 alkoxy C1-C4 alkoxy C1-C4 alkoxy group, a C2-C8 acyloxy group, a C2-C8 halogenoacyloxy group, a methylenedioxy group, a trifluoromethyl group, a phosphate group (i.e., —OP(O) (OH)2) or a salt thereof, a sulfate group (i.e., —OSO3H) or a salt thereof, a glycopyranosyl group or a salt thereof, a phosphate ester of a glycopyranosyl group or a salt of the ester, a sulfate ester of a glycopyranosyl group or a salt of the ester, or a piperidinopiperidinocarbonyloxy group], an ester thereof, or a salt thereof.
    • 本发明提供抑制BCRP的药物。 作为活性成分,含有下述式(1)表示的二苯基丙烯腈衍生物的乳
      球癌抗性蛋白质抑制剂:[其中,8个相同或不同的8个R代表氢原子,羟基 基团,硝基,氨基,乙酰氨基(-NHCOCH 3 SO 3); 氰基(-CN基); 甲酰基(-CHO基),-COOR 1(R 1是氢或C 1 -C 4烷基),-O(CH 2) )nOR 2(n = 1-7:R 2是氢或C 1 -C 4烷基),-OOCCH 2 (R 3)是氢,C 1 -C 4烷基,(Z)-2-(3,4-二氯苯基) 二甲氧基 - 苯基)-3-(4-羟基 - 苯基) - 丙烯腈或糖吡喃糖基),C1-C8烷氧基,C1-C4烷基,卤素原子,C1-C4烷氧基C1-C4烷氧基C1- C4烷氧基,C2-C8酰氧基,C2-C8卤代酰氧基,亚甲二氧基,三氟甲基,磷酸基(即-OP(O)(OH)2))或 其盐,硫酸基(即-OSO 3 H)或其盐,糖吡喃糖基或其盐,糖吡喃糖基的磷酸酯或酯的盐, 糖吡喃糖基的硫酸酯或酯的盐或哌啶子基哌啶羰基氧基],其酯或其盐。
    • 6. 发明申请
    • Breast cancer resistance protein (bcrp) inhibitor
    • 乳腺癌抗性蛋白(bcrp)抑制剂
    • US20060128636A1
    • 2006-06-15
    • US10544064
    • 2004-02-03
    • Ryuta YamazakiYukiko NishiyamaTomio FurutaTakeshi MatsuzakiHiroshi HatanoOh YoshidaMasato NagaokaRitsuo AiyamaShusuke HashimotoYoshikazu Sugimoto
    • Ryuta YamazakiYukiko NishiyamaTomio FurutaTakeshi MatsuzakiHiroshi HatanoOh YoshidaMasato NagaokaRitsuo AiyamaShusuke HashimotoYoshikazu Sugimoto
    • A61K31/7034A61K31/277A61K31/66
    • C07D211/58A61K31/277A61K31/7034C07C255/37C07D317/60
    • The invention provides a drug which inhibits BCRP. A breast cancer resistance protein inhibitor containing, as an active ingredient, a diphenylacrylonitrile derivative represented by the following formula (1): [wherein, each of 8 R's, which are the same or different from one another, represents a hydrogen atom, a hydroxyl group, a nitro group, an amino group, an acetylamino group (—NHCOCH3 group); a cyano group (—CN group); a formyl group (—CHO group), —COOR1 (R1 is hydrogen or C1-C4 alkyl), —O(CH2)nCOOR2 (n=1−7: R2 is hydrogen or C1-C4 alkyl), —OOCCH2CH2COOR3 (R3 is hydrogen, C1-C4 alkyl, (Z)-2-(3,4-dimethoxy-phenyl)-3-(4-hydroxy-phenyl)-acrylonitrile, or glycopyranosyl), a C1-C8 alkoxy group, a C1-C4 alkyl group, a halogen atom, a C1-C4 alkoxy C1-C4 alkoxy C1-C4 alkoxy group, a C2-C8 acyloxy group, a C2-C8 halogenoacyloxy group, a methylenedioxy group, a trifluoromethyl group, a phosphate group (i.e., —OP(O) (OH)2) or a salt thereof, a sulfate group (i.e., —OSO3H) or a salt thereof, a glycopyranosyl group or a salt thereof, a phosphate ester of a glycopyranosyl group or a salt of the ester, a sulfate ester of a glycopyranosyl group or a salt of the ester, or a piperidinopiperidinocarbonyloxy group], an ester thereof, or a salt thereof.
    • 本发明提供抑制BCRP的药物。 作为活性成分,含有下述式(1)表示的二苯基丙烯腈衍生物的乳
      球癌抗性蛋白质抑制剂:[其中,8个相同或不同的8个R代表氢原子,羟基 基团,硝基,氨基,乙酰氨基(-NHCOCH 3 SO 3); 氰基(-CN基); 甲酰基(-CHO基),-COOR 1(R 1是氢或C 1 -C 4烷基),-O(CH 2) )nOR 2(n = 1-7:R 2是氢或C 1 -C 4烷基),-OOCCH 2 (R 3)是氢,C 1 -C 4烷基,(Z)-2-(3,4-二氯苯基) 二甲氧基 - 苯基)-3-(4-羟基 - 苯基) - 丙烯腈或糖吡喃糖基),C1-C8烷氧基,C1-C4烷基,卤素原子,C1-C4烷氧基C1-C4烷氧基C1- C4烷氧基,C2-C8酰氧基,C2-C8卤代酰氧基,亚甲二氧基,三氟甲基,磷酸基(即-OP(O)(OH)2))或 其盐,硫酸基(即-OSO 3 H)或其盐,糖吡喃糖基或其盐,糖吡喃糖基的磷酸酯或酯的盐, 糖吡喃糖基的硫酸酯或酯的盐或哌啶子基哌啶羰基氧基],其酯或其盐。
    • 7. 发明授权
    • Phenanthroindolizidine compound and NFκB inhibitor containing same as active ingredient
    • 菲并吲哚哩啶化合物和含有与活性成分相同的NF&kgr B抑制剂
    • US09174979B2
    • 2015-11-03
    • US13125698
    • 2009-10-23
    • Takashi IkedaSeigo SawadaTakashi YaegashiTakeshi MatsuzakiShusuke HashimotoRyuta Yamazaki
    • Takashi IkedaSeigo SawadaTakashi YaegashiTakeshi MatsuzakiShusuke HashimotoRyuta Yamazaki
    • C07D471/04A61K31/437A61P29/00A61P35/00C07D491/147
    • C07D471/04C07D491/147
    • A novel compound having an excellent NFκB inhibitory effect is provided and specifically disclosed is a compound represented by the following formula (1) or a salt thereof:wherein, R1 represents a hydrogen atom, a lower alkyl group, a lower alkyloxy group, or a halogen atom;R2 represents a hydroxyl group, or a lower alkyloxy group;R3 represents a hydrogen atom, a lower alkyl group, or a halogen atom;R4 represents a hydrogen atom or a lower alkyloxy group;R5 represents a hydrogen atom, a lower alkyloxy group, a halogen atom, a hydroxyl group, or a methylenedioxy group formed together with R6 or an isopropylidenedioxy group formed together with R6;R6 represents a hydrogen atom, a lower alkyloxy group, or a methylenedioxy group formed together with R5 or an isopropylidenedioxy group formed together with R5;R7 represents a hydrogen atom or a lower alkyl group; andR8 represents a hydrogen atom, a hydroxyl group, an amino group, or a lower alkylcarbonyloxy group (excluding the case where R1, R3, R4 and R7 are hydrogen atoms, R2 and R8 are hydroxyl groups, and R5 and R6 are methoxy groups).
    • 提供了具有优异的NF&Kgr B抑制效果的新化合物,具体公开了下式(1)表示的化合物或其盐:其中,R1表示氢原子,低级烷基,低级烷氧基, 或卤素原子; R2表示羟基或低级烷氧基; R3表示氢原子,低级烷基或卤素原子; R4表示氢原子或低级烷氧基; R5表示与R6一起形成的与R6或异丙烯二氧基一起形成的氢原子,低级烷氧基,卤素原子,羟基或亚甲二氧基; R6表示与R5一起形成的氢原子,低级烷氧基或亚甲二氧基,或与R5形成的异丙烯二氧基; R7表示氢原子或低级烷基; 并且R 8表示氢原子,羟基,氨基或低级烷基羰基氧基(R 1,R 3,R 4和R 7为氢原子的情况除外,R 2和R 8为羟基,R 5和R 6为甲氧基 )。
    • 8. 发明授权
    • Phenanthroindolizidine derivative and NFκB inhibitor containing same as active ingredient
    • 菲咯啉二氮茚衍生物和含有与活性成分相同的NFkappaB抑制剂
    • US08569327B2
    • 2013-10-29
    • US13124554
    • 2009-10-23
    • Takashi IkedaSeigo SawadaTakashi YaegashiTakeshi MatsuzakiShusuke HashimotoRyuta Yamazaki
    • Takashi IkedaSeigo SawadaTakashi YaegashiTakeshi MatsuzakiShusuke HashimotoRyuta Yamazaki
    • A61K31/403C07D221/18
    • C07D471/04
    • A novel compound having an excellent NFκB inhibitory effect is provided. Specifically disclosed is a compound represented by the following formula (1) or a salt thereof: wherein, R1 represents a hydrogen atom, a lower alkyl group, or the like; R2 represents a hydrogen atom, a lower alkyl group, a halogen atom, or the like; R3 represents a hydrogen atom, a lower alkyl group, a hydroxyl group, or a halogen atom; R4 represents a hydrogen atom or a lower alkyloxy group; R5 represents a hydrogen atom, a lower alkyloxy group, a halogen atom, a hydroxyl group, or a methylenedioxy group formed together with R6 or an isopropylidenedioxy group formed together with R6; R6 represents a hydrogen atom, a lower alkyloxy group, or a methylenedioxy group formed together with R5 or an isopropylidenedioxy group formed together with R5; R7 represents a hydrogen atom or a lower alkyl group; and R8 represents a hydrogen atom, a hydroxyl group, an amino group, a lower alkylcarbonyloxy group, or a halogen atom.
    • 提供了具有优异NFκB抑制作用的新型化合物。 具体公开的是由下式(1)表示的化合物或其盐:其中,R1表示氢原子,低级烷基等; R2表示氢原子,低级烷基,卤素原子等; R3表示氢原子,低级烷基,羟基或卤素原子; R4表示氢原子或低级烷氧基; R5表示与R6一起形成的与R6或异丙烯二氧基一起形成的氢原子,低级烷氧基,卤素原子,羟基或亚甲二氧基; R6表示与R5一起形成的氢原子,低级烷氧基或亚甲二氧基,或与R5形成的异丙烯二氧基; R7表示氢原子或低级烷基; R8表示氢原子,羟基,氨基,低级烷基羰基氧基或卤素原子。
    • 9. 发明申请
    • PHENANTHROINDOLIZIDINE COMPOUND AND NFkB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT
    • 苯并噻唑类化合物和含有其作为活性成分的NFkB抑制剂
    • US20110201638A1
    • 2011-08-18
    • US13125698
    • 2009-10-23
    • Takashi IkedaSeigo SawadaTakashi YaegashiTakeshi MatsuzakiShusuke HashimotoRyuta Yamazaki
    • Takashi IkedaSeigo SawadaTakashi YaegashiTakeshi MatsuzakiShusuke HashimotoRyuta Yamazaki
    • A61K31/437C07D471/04A61P29/00A61P35/00
    • C07D471/04C07D491/147
    • A novel compound having an excellent NFκB inhibitory effect is provided and specifically disclosed is a compound represented by the following formula (1) or a salt thereof:wherein, R1 represents a hydrogen atom, a lower alkyl group, a lower alkyloxy group, or a halogen atom; R2 represents a hydroxyl group, or a lower alkyloxy group; R3 represents a hydrogen atom, a lower alkyl group, or a halogen atom; R4 represents a hydrogen atom or a lower alkyloxy group; R5 represents a hydrogen atom, a lower alkyloxy group, a halogen atom, a hydroxyl group, or a methylenedioxy group formed together with R6 or an isopropylidenedioxy group formed together with R6; R6 represents a hydrogen atom, a lower alkyloxy group, or a methylenedioxy group formed together with R5 or an isopropylidenedioxy group formed together with R5; R7 represents a hydrogen atom or a lower alkyl group; and R8 represents a hydrogen atom, a hydroxyl group, an amino group, or a lower alkylcarbonyloxy group (excluding the case where R1, R3, R4 and R7 are hydrogen atoms, R2 and R8 are hydroxyl groups, and R5 and R6 are methoxy groups).
    • 提供了具有优异的NF&Kgr B抑制效果的新化合物,具体公开了下式(1)表示的化合物或其盐:其中,R1表示氢原子,低级烷基,低级烷氧基, 或卤素原子; R2表示羟基或低级烷氧基; R3表示氢原子,低级烷基或卤素原子; R4表示氢原子或低级烷氧基; R5表示与R6一起形成的与R6或异丙烯二氧基一起形成的氢原子,低级烷氧基,卤素原子,羟基或亚甲二氧基; R6表示与R5一起形成的氢原子,低级烷氧基或亚甲二氧基,或与R5形成的异丙烯二氧基; R7表示氢原子或低级烷基; 并且R 8表示氢原子,羟基,氨基或低级烷基羰基氧基(R 1,R 3,R 4和R 7为氢原子的情况除外,R 2和R 8为羟基,R 5和R 6为甲氧基 )。